Assessment of QTc Prolongation for Non-cardiac-related Drugs from a Drug Development Perspective
Overview
Authors
Affiliations
It is increasingly likely that non-cardiac-related drugs will need to be routinely analyzed for their ability to prolong cardiac repolarization. This leads to potential problems for drug companies in general and statisticians in particular. A number of issues immediately arise in regard to answering the question, "Does drug X prolong cardiac repolarization?" These include identifying what is the desired outcome, what is the dependent variable, and what analysis method should be used. The purpose of this article is bring to to light some of the issues regarding the analysis of QTc data, the advantages and disadvantages of these analysis methods, and some general recommendations.
Diemberger I, Massaro G, Cubelli M, Rubino D, Quercia S, Martignani C Eur J Clin Pharmacol. 2015; 71(8):1001-9.
PMID: 26028320 DOI: 10.1007/s00228-015-1874-3.
The role of concentration-effect relationships in the assessment of QTc interval prolongation.
France N, Della Pasqua O Br J Clin Pharmacol. 2014; 79(1):117-31.
PMID: 24938719 PMC: 4294082. DOI: 10.1111/bcp.12443.
Chain A, Dieleman J, van Noord C, Hofman A, Stricker B, Danhof M Br J Clin Pharmacol. 2013; 76(6):964-72.
PMID: 23617533 PMC: 3845320. DOI: 10.1111/bcp.12151.
Designing and interpreting the results of first-time-to-man studies.
Patat A Dialogues Clin Neurosci. 2011; 2(3):203-12.
PMID: 22033693 PMC: 3181605.
Salvi V, Karnad D, Panicker G, Kothari S Br J Pharmacol. 2009; 159(1):34-48.
PMID: 19775279 PMC: 2823350. DOI: 10.1111/j.1476-5381.2009.00427.x.